SG11201608403TA - Epigenetic modification of mammalian genomes using targeted endonucleases - Google Patents

Epigenetic modification of mammalian genomes using targeted endonucleases

Info

Publication number
SG11201608403TA
SG11201608403TA SG11201608403TA SG11201608403TA SG11201608403TA SG 11201608403T A SG11201608403T A SG 11201608403TA SG 11201608403T A SG11201608403T A SG 11201608403TA SG 11201608403T A SG11201608403T A SG 11201608403TA SG 11201608403T A SG11201608403T A SG 11201608403TA
Authority
SG
Singapore
Prior art keywords
epigenetic modification
mammalian genomes
targeted endonucleases
endonucleases
targeted
Prior art date
Application number
SG11201608403TA
Other languages
English (en)
Inventor
Gregory D Davis
Qiaohua Kang
Original Assignee
Sigma Aldrich Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Aldrich Co Llc filed Critical Sigma Aldrich Co Llc
Publication of SG11201608403TA publication Critical patent/SG11201608403TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
SG11201608403TA 2014-04-28 2015-04-24 Epigenetic modification of mammalian genomes using targeted endonucleases SG11201608403TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461985205P 2014-04-28 2014-04-28
PCT/US2015/027541 WO2015167959A1 (fr) 2014-04-28 2015-04-24 Modification épigénétique de génomes de mammifères à l'aide d'endonucléases ciblées

Publications (1)

Publication Number Publication Date
SG11201608403TA true SG11201608403TA (en) 2016-11-29

Family

ID=54359184

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608403TA SG11201608403TA (en) 2014-04-28 2015-04-24 Epigenetic modification of mammalian genomes using targeted endonucleases

Country Status (6)

Country Link
US (2) US20170051354A1 (fr)
EP (1) EP3137633A4 (fr)
JP (1) JP2017517250A (fr)
CN (1) CN106460050A (fr)
SG (1) SG11201608403TA (fr)
WO (1) WO2015167959A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037001A2 (fr) 2008-09-26 2010-04-01 Immune Disease Institute, Inc. Oxydation sélective de 5-méthylcytosine par des protéines de la famille tet
ES2669214T3 (es) 2011-12-13 2018-05-24 Oslo Universitetssykehus Hf Procedimientos y kits para la detección de estado de metilación
ES2786984T3 (es) 2012-11-30 2020-10-14 Cambridge Epigenetix Ltd Agente oxidante para nucleótidos modificados
WO2017059245A2 (fr) 2015-09-30 2017-04-06 Trustees Of Boston University Coupe-circuits microbiens de type deadman et passcode
CA3011484A1 (fr) * 2016-01-14 2017-07-20 Memphis Meats, Inc. Procedes d'extension de capacite de replication de cellules somatiques pendant un processus de culture ex vivo
US11078481B1 (en) 2016-08-03 2021-08-03 KSQ Therapeutics, Inc. Methods for screening for cancer targets
US11078483B1 (en) 2016-09-02 2021-08-03 KSQ Therapeutics, Inc. Methods for measuring and improving CRISPR reagent function
EP4424837A3 (fr) 2017-05-06 2024-12-11 Upside Foods, Inc. Compositions et procédés permettant d'augmenter la densité de culture d'une biomasse cellulaire dans une infrastructure de culture
AU2018286393A1 (en) * 2017-06-15 2020-01-30 College Of Medicine Pochon Cha University Industry-Academic Cooperation Foundation Genome editing system for repeat expansion mutation
EP3638777A4 (fr) 2017-07-13 2021-05-12 Memphis Meats, Inc. Compositions et procédés pour augmenter l'efficacité de cultures cellulaires utilisées pour la production d'aliments
CN108624622A (zh) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 一种基于CRISPR-Cas9系统构建的能分泌小鼠白细胞介素-6的基因工程细胞株
JPWO2021171688A1 (fr) * 2020-02-26 2021-09-02
DE102020205076B3 (de) * 2020-04-22 2021-09-02 Universität Ulm, Körperschaft des öffentlichen Rechts Verfahren zur Bereitstellung einer Medikamentenkombination und Datenträger mit Software
CA3187549A1 (fr) 2020-07-30 2022-02-03 Cambridge Epigenetix Limited Compositions et procedes d'analyse d'acides nucleiques
CN112430662B (zh) * 2020-12-11 2022-02-22 中国医学科学院肿瘤医院 一种用于预测肺鳞癌预后风险的试剂盒及其应用
CN117813099A (zh) * 2021-08-06 2024-04-02 领康冠军有限公司 基于miRNA的组合物及其使用方法
JP2024538697A (ja) * 2021-10-08 2024-10-23 マイクロノーマ，インク． メタエピゲノミクスベースの疾患診断法
CN114574493A (zh) * 2022-04-02 2022-06-03 中国科学院遗传与发育生物学研究所 一种编辑绵羊SOCS2基因的sgRNA组合、扩增用引物和应用
WO2023240152A1 (fr) 2022-06-07 2023-12-14 Upside Foods, Inc. Ingénierie de lignées cellulaires permettant une prolifération dans des formulations de milieux sans facteur de croissance

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4152413A (en) * 1978-08-18 1979-05-01 Chromalloy American Corporation Oral vaccine for swine dysentery and method of use
ES2109362T3 (es) * 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
AU4133397A (en) * 1996-10-28 1998-05-22 Pfizer Inc. Oral vaccines for young animals with an enteric coating
GB9818591D0 (en) * 1998-08-27 1998-10-21 Danbiosyst Uk Pharmaceutical composition
WO2001077377A2 (fr) * 2000-04-06 2001-10-18 Epigenomics Ag Diagnostic de maladies associees a la replication de l'adn
US20090269736A1 (en) * 2002-10-01 2009-10-29 Epigenomics Ag Prognostic markers for prediction of treatment response and/or survival of breast cell proliferative disorder patients
WO2007014275A2 (fr) * 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Integration et expression ciblees de sequences d'acides nucleiques exogenes
WO2011026111A1 (fr) * 2009-08-31 2011-03-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Distribution par voie orale d'un vaccin au gros intestin pour induire une immunité mucosale
WO2011082436A1 (fr) * 2010-01-04 2011-07-07 Lineagen, Inc. Biomarqueurs de méthylation d'adn de la fonction pulmonaire
JP2013518602A (ja) * 2010-02-09 2013-05-23 サンガモ バイオサイエンシーズ， インコーポレイテッド 部分的に一本鎖のドナー分子による標的化ゲノム改変
US20130273154A1 (en) * 2011-03-02 2013-10-17 Joseph M. Fayad Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
US8902648B2 (en) * 2011-07-26 2014-12-02 Micron Technology, Inc. Dynamic program window determination in a memory device
JP6203816B2 (ja) * 2012-03-29 2017-09-27 セラバイオーム，エルエルシー 回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤
WO2013158309A2 (fr) * 2012-04-18 2013-10-24 The Board Of Trustees Of The Leland Stanford Junior University Ciblage génique non disruptif

Also Published As

Publication number Publication date
CN106460050A (zh) 2017-02-22
US20170051354A1 (en) 2017-02-23
EP3137633A4 (fr) 2017-11-29
WO2015167959A1 (fr) 2015-11-05
US20190271041A1 (en) 2019-09-05
JP2017517250A (ja) 2017-06-29
EP3137633A1 (fr) 2017-03-08

Similar Documents

Publication Publication Date Title
EP3137633A4 (fr) Modification épigénétique de génomes de mammifères à l'aide d'endonucléases ciblées
ES2750661T5 (en) Methods for purification of messenger rna
IL249619A0 (en) Analysis of nucleic acid sequences
SG11201609265RA (en) Characterizing states of subject
IL249637A0 (en) Methods and compositions for targeted genetic modifications and methods of use
AP2016009496A0 (en) Substituted spirocydic inhibitors of autotaxin
PL3218005T3 (pl) Związki oddziałujące z glikanami i sposoby ich zastosowania
PT3201361T (pt) Métodos de quantificação de adn acelular
ZA201702545B (en) Neuroactive compounds and methods of use thereof
SI3089971T1 (sl) Spojine in postopki za uporabo
IL248529B (en) Palladianolide pyridine compounds and methods of use
GB201415761D0 (en) Methods for detection of Nucleotide modification
PL3237356T3 (pl) Zastosowanie wyrobów ogniotrwałych
ZA201606450B (en) Compounds and their methods of use
SG10201408033VA (en) Photobioreactor
GB201402169D0 (en) Viral inhibitors
SG11201607445QA (en) Methods of modulating wars2
TWM490344U (en) Improved structure of grasping claws
GB201403697D0 (en) Compounds and methods of use
GB201417348D0 (en) Prodrugs of lxazomib
GB201417347D0 (en) Prodrugs of delanzomib
GB201508443D0 (en) Methods of identifying USP-binding compounds
PL3137475T3 (pl) Oczyszczanie epidaunorubicyny
GB201414314D0 (en) Manufacture of graphene
HUP1400294A2 (hu) Clopidogrel új alkalmazása